Bone Biologics will ask shareholders to approve a Reverse Stock Split ranging from 1-for-2 to 1-for-10 on September 28, alongside potential warrant-related share issuance. The vote matters because approval could authorize the Board to choose the reverse-split ratio and permit shares underlying certain warrants to be issued.
Key Highlights
- The proposed reverse stock split would range from 1-for-2 to 1-for-10, with the Board selecting the final ratio.
- Jeffrey Frelick received $426,269 in total compensation for 2025, while Deina Walsh received $263,136.
- The Annual Meeting was postponed from August 11, 2026, to September 28, 2026.
Bone Biologics Corp (NASDAQ: BBLGW) will put a potential reverse stock split before shareholders at its annual meeting on September 28, 2026. The proposed ratio ranges from 1-for-2 to 1-for-10, with the Board holding discretion over the final ratio.
Reverse Split And Warrant Approval
The proposal would give the Board discretion to select the ratio within the proposed range if shareholders approve the measure. Shareholders will also be asked to approve an adjournment if there are insufficient votes to approve the proposals or establish a quorum.
Directors, Pay And Auditor
The ballot includes the election of four directors.
The meeting was postponed from August 11, 2026, to September 28, 2026. The revised meeting will be held at Bone Biologics’ offices in Burlington, Massachusetts.
Executive Compensation Totals
Jeffrey Frelick, the company’s Chief Executive Officer and President, received $426,269 in total compensation for 2025. That amount included $300,000 in salary, $26,269 in option awards and $100,000 in non-equity incentive plan compensation. His total compensation for 2024 was $384,897, including $300,000 in salary, $30,788 in option awards and $54,109 in incentive compensation.
Deina Walsh, Chief Financial Officer, received $263,136 in total compensation for 2025. Her package included $200,000 in salary, $13,136 in option awards and $50,000 in non-equity incentive plan compensation. Walsh’s total compensation for 2024 was $242,448, comprising $200,000 in salary, $15,394 in option awards and $27,054 in incentive compensation.
The annual performance-based award program sets target opportunities at 50% of base salary for Frelick and 25% for Walsh.
The compensation table also reports compensation actually paid to Frelick of $430,788 for 2025 and $405,709 for 2024. Average compensation actually paid to non-PEO named executive officers was $265,394 in 2025 and $252,855 in 2024, while the corresponding total compensation figures were $263,136 and $242,448.
Net loss was $3,108,991 in 2025, $4,112,420 in 2024 and $8,948,731 in 2023.



Please wait processing your request...